Rare & Genetic · Clinical trials
Wilson's Disease Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About wilson's disease — and why its trials are hard
Wilson's disease is a rare autosomal-recessive disorder of copper metabolism caused by mutations in ATP7B, impairing biliary copper excretion and incorporation of copper into ceruloplasmin. Copper accumulates in the liver, brain, and other organs, producing hepatic disease (ranging from asymptomatic transaminitis to cirrhosis and acute liver failure) and neuropsychiatric manifestations (dystonia, tremor, dysarthria, psychiatric changes). Treatment relies on decades-old agents whose evidence base is largely historical and observational rather than modern randomized controlled trials: copper-chelating agents penicillamine (Cuprimine/Depen) and trientine (Syprine; trientine tetrahydrochloride, Cuvrior, approved 2022), plus zinc salts (zinc acetate, Galzin) that block intestinal copper absorption for maintenance. Lifelong therapy and adherence are essential; penicillamine carries notable toxicity and risk of paradoxical neurological worsening. The pipeline is modest: bis-choline tetrathiomolybdate (ALXN1840/WTX101), a novel copper-protein-binding agent, has been studied in the Phase 3 CHELATE trial. Overall the field is characterized by effective but old drugs, sparse trial data, and unmet need for better-tolerated, faster-acting decoppering therapies.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| penicillamine (Cuprimine / Depen) | 1970s (era of approval) | First-line copper chelation for symptomatic Wilson's disease | No modern randomized pivotal trial; approval and use based on historical/observational evidence | Copper decoppering (urinary copper excretion) and clinical/biochemical stabilization | Effective decoppering historically; limited by toxicity and risk of early neurological worsening (unverified quantitative magnitude) |
| trientine (trientine tetrahydrochloride) (Syprine / Cuvrior) | 1985 (Syprine); 2022 (Cuvrior) | Copper chelation, including patients intolerant of penicillamine; Cuvrior for stable adults on maintenance | Cuvrior: CHELATE (Phase 3, vs penicillamine) | Non-inferiority based on serum non-ceruloplasmin-bound copper control | Trientine tetrahydrochloride met non-inferiority to penicillamine on copper control (unverified exact values) |
| zinc acetate (Galzin) | 1997 | Maintenance therapy and treatment of presymptomatic/pregnant patients (blocks intestinal copper absorption) | No modern randomized pivotal trial; observational evidence base | Maintenance of negative copper balance | Effective for maintenance; slower onset than chelators (unverified quantitative magnitude) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in wilson's disease development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| bis-choline tetrathiomolybdate (ALXN1840/WTX101) — CHELATE (Phase 3) | Reported to meet its primary copper-related endpoint but development did not advance to approval; regulatory/commercial path stalled (unverified) | Interpretation of a novel copper-mobilization endpoint versus standard-of-care and questions on clinical relevance of the biomarker complicated the program (unverified) |
Choosing the right endpoint
Primary endpoints that matter in wilson's disease trials
- 24-hour urinary copper excretion — Reflects chelator-mobilized copper; used to monitor decoppering and adherence
- Non-ceruloplasmin-bound ('free') copper — Estimates the toxic copper pool and is a core biomarker for treatment adequacy
- Neurological status (e.g., UWDRS) — Unified Wilson's Disease Rating Scale tracks neurological/functional change, including risk of paradoxical worsening
- Liver function and fibrosis markers — Assess hepatic response and progression across the disease spectrum
How iNGENū runs wilson's disease trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Wilson's Disease clinical trials — FAQs
Why are Wilson's disease treatments so old?
How is treatment chosen between chelators and zinc?
Are there newer drugs in development?
Ready to discuss your wilson's disease trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal